JP2012506402A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506402A5
JP2012506402A5 JP2011532609A JP2011532609A JP2012506402A5 JP 2012506402 A5 JP2012506402 A5 JP 2012506402A5 JP 2011532609 A JP2011532609 A JP 2011532609A JP 2011532609 A JP2011532609 A JP 2011532609A JP 2012506402 A5 JP2012506402 A5 JP 2012506402A5
Authority
JP
Japan
Prior art keywords
pramlintide
carboxy
carboxynonadecanoylamino
butyryl
his17
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506402A (ja
JP5703226B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/063724 external-priority patent/WO2010046357A1/en
Publication of JP2012506402A publication Critical patent/JP2012506402A/ja
Publication of JP2012506402A5 publication Critical patent/JP2012506402A5/ja
Application granted granted Critical
Publication of JP5703226B2 publication Critical patent/JP5703226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532609A 2008-10-21 2009-10-20 アミリン誘導体 Active JP5703226B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08167154 2008-10-21
EP08167154.7 2008-10-21
EP09161372 2009-05-28
EP09161372.9 2009-05-28
PCT/EP2009/063724 WO2010046357A1 (en) 2008-10-21 2009-10-20 Amylin derivatives

Publications (3)

Publication Number Publication Date
JP2012506402A JP2012506402A (ja) 2012-03-15
JP2012506402A5 true JP2012506402A5 (enExample) 2012-12-06
JP5703226B2 JP5703226B2 (ja) 2015-04-15

Family

ID=41728511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532609A Active JP5703226B2 (ja) 2008-10-21 2009-10-20 アミリン誘導体

Country Status (7)

Country Link
US (1) US8895504B2 (enExample)
EP (1) EP2340261B1 (enExample)
JP (1) JP5703226B2 (enExample)
CN (1) CN102197049B (enExample)
ES (1) ES2662501T3 (enExample)
TW (1) TW201018479A (enExample)
WO (1) WO2010046357A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400698A (zh) 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
EP2718315B1 (en) * 2011-06-10 2017-12-27 Novo Nordisk A/S Pramlintide derivatives
PL2838914T3 (pl) 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
CN104327162A (zh) * 2014-09-28 2015-02-04 苏州普罗达生物科技有限公司 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
CN106554405B (zh) * 2015-09-30 2020-04-24 深圳翰宇药业股份有限公司 一种多肽及其用途、制备方法
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
AU2019357621B2 (en) * 2018-10-11 2025-04-03 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
WO2020225781A1 (en) * 2019-05-08 2020-11-12 Auckland Uniservices Limited Peptide conjugate amylin agonists and uses thereof
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
SMT202600248T1 (it) 2020-12-16 2026-07-16 Medimmune Ltd Polipeptidi e usi di essi
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
IL312600B2 (en) 2022-05-30 2025-12-01 Zealand Pharma As Liquid formulations of amylin analogs
GB202217575D0 (en) * 2022-11-24 2023-01-11 Imperial College Innovations Ltd Novel compounds
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
WO2026046286A1 (zh) * 2024-08-29 2026-03-05 杭州九源基因生物医药股份有限公司 一种人胰淀素类似物及其衍生物与医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1474164B1 (en) * 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
KR20080003849A (ko) * 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법
AU2006312307A1 (en) 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives

Similar Documents

Publication Publication Date Title
CN114901682B (zh) 胰岛素衍生物
US9382304B2 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2008533105A5 (enExample)
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
JP5969461B2 (ja) Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
JP2013523618A5 (enExample)
JP2022031787A (ja) グルカゴン及びglp-1共アゴニスト化合物
US20150133373A1 (en) Transmucosal delivery of engineered polypeptides
RU2007134156A (ru) Ацилированные glp-1 соединения
JP2014516049A5 (enExample)
RU2020136305A (ru) Производные gip и пути их применения
JP2014519509A5 (enExample)
JP2013543853A5 (enExample)
JP7443315B2 (ja) アシル化オキシントモジュリンペプチド類似体
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
JP2014519511A5 (enExample)
JP2022504153A5 (enExample)
JP2011524420A5 (enExample)
JP2013523619A5 (enExample)
RU2013156937A (ru) Полипептиды
JP2014519510A5 (enExample)
US20160207974A1 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
JP2010538049A5 (enExample)
JP2012529463A (ja) 2型糖尿病を治療するための、glp−1とfgf21との組合せ
JP2012512903A5 (enExample)